Advanced in Non-Alcoholic Fatty Liver Disease

Dr. Marcelo Kugelmas

Gastroenterology
10103 Ridgegate Pkwy, Ste 312, 
Lone Tree, CO 
Accepting New Patients
Offers Telehealth
32 Years of Experience
Advanced in Non-Alcoholic Fatty Liver Disease
10103 Ridgegate Pkwy, Ste 312, 
Lone Tree, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marcelo Kugelmas is a Gastroenterologist in Lone Tree, Colorado. Dr. Kugelmas has been practicing medicine for over 32 years and is rated as an Advanced provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Cirrhosis, Visceromegaly, Non-Alcoholic Fatty Liver Disease, Endoscopy, and Colonoscopy. Dr. Kugelmas is currently accepting new patients.

His clinical research consists of co-authoring 24 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles and participated in 4 clinical trials in the study of Non-Alcoholic Fatty Liver Disease.

Graduate Institution
University Of Buenos Aires
Residency
LAC/USC Medical Center
Specialties
Gastroenterology
Licenses
Internal Medicine in CO
Fellowships
Cleveland Clinic Foundation
University of Kentucky College of Medicine
Hospital Affiliations
Hca-Healthone Dba Swedish Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

South Denver Gastroenterology, PC
10103 Ridgegate Pkwy, Ste 312, Lone Tree, CO 80124

Additional Areas of Focus

Dr. Kugelmas has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

24 Total Publications

Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
Journal: Journal of hepatology
Published: March 21, 2025
Similar Doctors
Distinguished in Non-Alcoholic Fatty Liver Disease
Dr. Carl S. Swendsen
Gastroenterology
Distinguished in Non-Alcoholic Fatty Liver Disease
Dr. Carl S. Swendsen
Gastroenterology

Associates In Gastroenterology, PC

2940 N Circle Dr, 
Colorado Springs, CO 
 (54.9 miles away)
719-635-7321
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carl Swendsen is a Gastroenterologist in Colorado Springs, Colorado. Dr. Swendsen is rated as a Distinguished provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Familial Adenomatous Polyposis, Turcot Syndrome, Gastrectomy, and Endoscopy. Dr. Swendsen is currently accepting new patients.

Distinguished in Non-Alcoholic Fatty Liver Disease
Dr. Matthew E. Drew
Gastroenterology
Distinguished in Non-Alcoholic Fatty Liver Disease
Dr. Matthew E. Drew
Gastroenterology

Associates In Gastroenterology, PC

2940 N Circle Dr, 
Colorado Springs, CO 
 (54.9 miles away)
719-635-7321
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Drew is a Gastroenterologist in Colorado Springs, Colorado. Dr. Drew is rated as a Distinguished provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Visceromegaly, Turcot Syndrome, Colonoscopy, and Endoscopy. Dr. Drew is currently accepting new patients.

Advanced in Non-Alcoholic Fatty Liver Disease
Dr. Shikha S. Sundaram
Pediatric Gastroenterology | Gastroenterology
Advanced in Non-Alcoholic Fatty Liver Disease
Dr. Shikha S. Sundaram
Pediatric Gastroenterology | Gastroenterology
13123 E 16th Ave, 
Aurora, CO 
 (9.9 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shikha Sundaram is a Pediatric Gastroenterologist and a Gastroenterologist in Aurora, Colorado. Dr. Sundaram is rated as a Distinguished provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. Her top areas of expertise are Alagille Syndrome, Cholestasis, Biliary Atresia, Liver Transplant, and Endoscopy. Dr. Sundaram is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kugelmas's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile